R O'Dell 0 Joel Kremer 3 0 Department of Rheumatology, Division of Rheumatology and immunology, University of n ebraska Medical center and the Omaha VA , Omaha, ne, UsA , USA 1 Department of internal
Shan is an employee of Corrona, LLC. Joel Kremer is an employee of Corrona, LLC. Kimberly J. Dandreo is an employee of Corrona, LLC. Corrona, LLC was a paid consultant to Pfizer Inc in connection with
Introduction Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and...
Background We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients. Methods We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010–31 May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based on the...
Introduction Patients with active rheumatoid arthritis (RA) despite anti–tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies. The objective of this analysis was to...
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Method In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive: tofacitinib 5 mg BID or tofacitinib 10 mg BID for the duration of the study, or...
AuthorsSearch for Vibeke Strand in:PubMed • Google Scholar Search for Joel Kremer in:PubMed • Google Scholar Search for Gene Wallenstein in:PubMed • Google Scholar Search for Keith S. Kanik in:PubMed • Google
Background Factors associated with care concordant with the American College of Rheumatology (ACR) recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) are unknown. Methods We identified a national cohort of biologic-naive patients with RA with visits between December 2008 and February 2013. Treatment acceleration (initiation...
ScholarSearch for Joel Kremer in:Nature Research journals • PubMed • Google ScholarSearch for Dimitrios A Pappas in:Nature Research journals • PubMed • Google ScholarSearch for Alexandros Kanterakis in:Nature
., Lindsey Criswell , Larry Moreland, Lars Klareskog, Saedis Saevarsdottir 7 Cheng Zhao, Members of the Rheumatoid Arthritis Challenge Consortium , Jeff Greenberg, Joel Kremer 8 Tao Wang, Krister Wennerberg
ScholarSearch for Jeff Greenberg in:Nature Research journals • PubMed • Google ScholarSearch for Joel Kremer in:Nature Research journals • PubMed • Google ScholarSearch for Kaleb Michaud in:Nature Research
